Characterization of long-term survival in Medicare patients undergoing arteriovenous hemodialysis access

医学 危险系数 透析 血液透析 动静脉瘘 置信区间 比例危险模型 内科学 外科
作者
Matthew R. Smeds,Thomas W. Cheng,Elizabeth G. King,Michael Williams,Alik Farber,Vipul C. Chitalia,Jeffrey J. Siracuse
出处
期刊:Journal of Vascular Surgery [Elsevier BV]
卷期号:79 (4): 925-930
标识
DOI:10.1016/j.jvs.2023.12.031
摘要

Patients undergoing arteriovenous (AV) access creation for hemodialysis often have significant comorbidities. Our goal was to quantify the long-term survival and associated risks factors for long-term mortality in these patients to aid in optimization of goals and expectations. The Vascular Implant Surveillance and Interventional Outcomes Network (VISION) Vascular Quality Initiative Medicare linked data was used to assess long-term survival in the HD registry. Demographics, comorbidities, and interventions were recorded. As the majority of HD patients are provided Medicare, Medicare linkage was used to obtain survival data. Multivariable analysis was used to identify independent associations with mortality. There were 13,945 AV access patients analyzed including 10,872 (78%) AV fistulas and 3,073 (22%) AV grafts. The median age was 67 year and 56% of patients were male. Approximately one third had a prior AV access and 44.7% had prior tunneled dialysis catheters. Patients receiving an AV fistula, compared to AV grafts, were more often younger, male, white, obese, independently ambulatory, preoperatively living at home, and less often have a prior AV access and tunneled dialysis catheters (P<.05 for all). The 5-year mortality overall was 62.9% with 61.2% for AV fistulas and 68.8% for AV grafts (P<.001). On multivariable analysis for 5 year mortality, non-ambulatory status (HR 1.67, 95% CI 1.53 – 1.83, P<.001), lower extremity access (HR 1.67, 95% CI 1.35 – 2.05, P<.001), HIV/AIDS (HR 1.44, 95% CI 1.13 – 1.82, P<.001), White race (HR 1.43, 95% CI 1.35 – 1.51, P<.001), congestive heart failure (HR 1.33, 95% CI 1.26 – 1.41, P<.001), chronic obstructive pulmonary disease (HR 1.23, 95% CI 1.15 – 1.31, P<.001), and AV graft placement (HR 1.12, 95% CI 1.02 – 1.23, P = .016) were most associated with poor survival. Factors associated with improved survival were never smoking (HR .73, 95% CI .67 – .79, P<.001), prior/quit smoking (HR .78, 95% CI .72 – .84, P<.001), preoperative home living (HR .75, 95% CI .68 – .83, P<.001) and hypertension (HR .89, 95% CI .8 – .99, P=.03). Long-term survival in Medicare patients undergoing AV access creation is poor with nearly two-thirds of patients having died at 5 years. There are many modifiable risk factors that may improve survival in these patients and give an opportunity for transplantation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
汉堡包应助yu采纳,获得10
2秒前
3秒前
暴躁的马里奥完成签到,获得积分10
4秒前
4秒前
威武鸽子发布了新的文献求助10
5秒前
猪猪侠完成签到,获得积分10
5秒前
5秒前
JohnLocke发布了新的文献求助10
7秒前
李健应助无奈可仁采纳,获得10
8秒前
Double发布了新的文献求助10
9秒前
小思完成签到 ,获得积分10
11秒前
sterne完成签到 ,获得积分10
16秒前
hcy发布了新的文献求助10
16秒前
16秒前
17秒前
nn完成签到,获得积分10
17秒前
义气玫瑰完成签到,获得积分10
18秒前
19秒前
20秒前
judy完成签到,获得积分20
20秒前
科研通AI6.1应助王苏欣采纳,获得10
21秒前
21秒前
TranYan发布了新的文献求助20
23秒前
祺仔发布了新的文献求助10
24秒前
思源应助是多多呀采纳,获得10
25秒前
LY完成签到,获得积分10
25秒前
无奈可仁发布了新的文献求助10
26秒前
整齐的之云完成签到,获得积分10
26秒前
yu发布了新的文献求助10
28秒前
LI完成签到,获得积分10
29秒前
冷傲的从雪完成签到 ,获得积分20
31秒前
Double完成签到,获得积分10
32秒前
蓝天发布了新的文献求助10
32秒前
傲娇菠萝完成签到,获得积分10
35秒前
科研通AI6.1应助圆圆采纳,获得10
36秒前
37秒前
emily完成签到,获得积分10
40秒前
41秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
AnnualResearch andConsultation Report of Panorama survey and Investment strategy onChinaIndustry 1000
機能性マイクロ細孔・マイクロ流体デバイスを利用した放射性核種の 分離・溶解・凝集挙動に関する研究 1000
卤化钙钛矿人工突触的研究 1000
Engineering for calcareous sediments : proceedings of the International Conference on Calcareous Sediments, Perth 15-18 March 1988 / edited by R.J. Jewell, D.C. Andrews 1000
Wolffs Headache and Other Head Pain 9th Edition 1000
Continuing Syntax 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6256438
求助须知:如何正确求助?哪些是违规求助? 8078860
关于积分的说明 16876439
捐赠科研通 5329425
什么是DOI,文献DOI怎么找? 2837282
邀请新用户注册赠送积分活动 1814472
关于科研通互助平台的介绍 1668792